Innovative medical science and technology
Forecast of investment direction
In recent years, with the continuous development of medical technology and people's continuous attention to health, the innovative pharmaceutical technology industry has received unprecedented attention and development opportunities. Innovative medicine not only plays an important role in the prevention and treatment of various diseases, but also has a decisive impact on the long-term development of the world pharmaceutical industry. Even in the cold winter of capital today, the heat in this field is still not reduced, based on the views of Dr. Wang Zhen who participated in the 8th Cell Biology Industry Conference and the 6th China Biomedical Innovation Cooperation Conference and Chengdu Biomedical Innovation Achievement Roadshow held by Chengdu High-tech Medical Association on November 29, 2023.
Dr. Wang Zhen, a partner of Mingfeng Capital, has more than 10 years of experience in blob.png multinational pharmaceutical companies and finance, and a postdoctoral fellow in biomedical returnees. He has won many honors, such as EU Erasmus Talent Program, Academic New Talent Award of the Ministry of Education, Jiangsu Double Innovation Program, Jiangsu Young and Middle-aged Leading Talents, and the first 10,000 People Program of Sichuan Province. He is also a master's supervisor of the School of Economics of Sichuan University. Managed 4 RMB funds and 1 USD fund, and led the investment in Aibo Medical (688050), Rui Ang Gene (688217), Juzi Biological (02367), Jinbo Biological (832982), Beijing Green Bamboo Biological (02480), Shanghai Hedi Medical, Beijing BaihuiWeikang, Well-known companies such as plastic surgery chain hospitals of the Chinese Academy of Medical Sciences have achieved 7 times the exit income of a single fund in 3 years, and have distributed income of more than 1 billion yuan.
一
Factors that have depressed global economic activity
The core key to the downturn in global economic activity is that there is no increment, adjusting to the stage of stock competition. The contradiction between the domestic competitive environment and the global competitive pattern has become more prominent, and the Sino-US relationship has become increasingly intensified, the reason is that the "cake" in the economic growth stage is rich enough to grow together, and now the "cake" has not disappeared, and can only compete with the stock "cake", which has led to the situation.
二
Innovative medical track periodic prediction
01 Cycle start: 2015
2015 is the year of the rise of China's new drug research and development industry, with historic standards. Fifteen years ago, China was the rise of generic medicines, the increase in medical insurance coverage, and 15 years later, the emergence of medical insurance control costs and themes, leading to changes in the development of the industry at this stage.
02 Periodic adjustment phase
As of today, 8 years have passed from 15 years to 23 years, according to Dr. Wang Zhen's science and technology cycle theory, a wave of cycle is coming to an end, but because the innovative drug industry is a long track lasting 20 to 30 years, it is now in the adjustment stage, and the enterprises that break out again at this stage cannot be considered successful even if they go public, only go to the world and achieve hundreds of billions of market value. To be known as the leading company in the innovative drug industry. Such as Kang Fang biological, Xinda biological, legendary biological and so on.
三
Four directions in the field of innovative medicine
01 Metabolizing drugs or future directions
Global new drug research and development focus: before 2020, it is an anti-cancer drug, and 10 years after 2020, it is a metabolic drug. The PD-1 drug K drug, which began in 2013, has created the king of medicine. In 2023, sales of more than 20 billion US dollars of Semaglutide, is expected to become the new king of medicine. Novo Nordisk has a market value of $440 billion, and Eli Lilly has a market value of $500 billion. Metabolic drugs Because a drug can treat many diseases, so at this time its direction is likely to be adjusted for multiple targets, of course, because of the characteristics of long-term use, so oral administration is also a direction.
In summary, metabolic drugs can pay more attention to the two directions of multi-target and oral administration.
02 Gene drugs and cell drugs can be concerned
Human drug development, it from small molecules to antibody protein drugs, and then to the current gene cell drugs, is such a process, but not necessarily which direction is correct, for example, so far small molecule drugs and antibody drugs have, but with the development of our industry, now may be the most new opportunities in gene drugs and cell drugs. Therefore, the path of innovative medicine may be carried out by small molecule drugs, antibody drugs, and cell drugs, which can be demonstrated from Colombotai and Legendary biology.
03 Globalization is sustainable
Domestic enterprises have made efforts towards the goal of globalization, and policies such as collection have led to external pursuit of incremental or become a logic, without globalization, the market value may be forever in place. The fact that the upfront payment for License-out in 2023 is now twice that of License-in may be proof in its favor.
04 Medical device companies need to create their own blood as soon as possible
The attractiveness of the existing serious medical treatment has declined, consumer medical projects have begun to rise, and only companies with revenue and profits can be listed
